复发性头颈部鳞癌再程放疗:国际专家共识推荐
该国际专家共识针对既往照射区域内复发或第二原发头颈部鳞状细胞癌的再程放疗,通过结构化专家共识流程与正式一致性评估制定。共识涵盖患者选择、影像、靶区勾画、治疗计划、剂量累积和毒性管理等关键领域,旨在提供实用指导并促进实践一致性。
要点
- 再程放疗可考虑用于部分既往照射区域内复发或第二原发头颈部鳞癌患者。
- 现代适形放疗技术(IMRT、质子治疗、SBRT)扩展了再程放疗的可行性。
- 证据异质性大,临床决策需综合患者表现、既往治疗和毒性风险。
核心结论
- 再程放疗可考虑用于部分既往照射区域内复发或第二原发头颈部鳞癌患者。
- 共识旨在提供涵盖患者选择、影像、靶区勾画、治疗计划、剂量累积和毒性管理的实用指导。
研究设计与样本
- 国际专家共识声明,由再程放疗协作组、欧洲放射肿瘤学会再程放疗焦点组和美国放射肿瘤学会认可。
- 通过结构化专家共识流程与正式一致性评估制定。
主要发现
- 现代适形放疗技术(包括调强放疗、质子治疗和立体定向体部放疗)的日益使用扩展了再程放疗在临床实践中的可行性。
- 证据仍存在异质性,临床选择因患者表现、既往治疗和毒性风险的显著变异而面临挑战。
关键数值与推荐
- 再程放疗可考虑用于部分既往照射区域内复发或第二原发头颈部鳞癌患者。
临床怎么用
- 共识提供共享临床框架,以促进更一致的实践、促进中心间沟通并支持未来研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reirradiation can be considered for some patients with recurrent or second primary head and neck squamous cell carcinoma arising within previously irradiated regions, a clinical scenario associated with few therapeutic options. The increasing use of modern conformal radiotherapy techniques, including intensity-modulated radiotherapy, proton therapy, and stereotactic body radiotherapy, has expanded the feasibility of reirradiation in clinical practice. However, evidence remains heterogeneous, and clinical choices are challenged by substantial variability in patient presentation, previous treatments, and toxicity risk. This international expert consensus statement aims to provide pragmatic guidance across key domains, including patient selection, imaging, target delineation, treatment planning, dose accumulation, and toxicity management. Developed through a structured expert consensus process with formal agreement assessment, this document reflects current expert practice. By offering a shared clinical framework, this consensus seeks to promote more consistent practice, facilitate communication across centres, and support future research efforts in this complex and evolving field.
引用
- Biau J, Beddok A, Sharma M, et al. Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology. Lancet Oncol. 2026. PMID: 42372755. doi:10.1016/S1470-2045(26)00174-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。